---
title: "U.S. stock market update: Sonnet BioTherapeutics up 17.80%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/257766247.md"
description: "Sonnet BioTherapeutics rose 17.80%; AbbVie rose 2.38%, with a transaction volume of $310 million; Roivant Sciences rose 10.83%, with a transaction volume of $184 million; Forte Biosciences rose 0.43%, with a transaction volume of $171 million; Amgen rose 1.13%, with a market capitalization of $148.7 billion"
datetime: "2025-09-17T15:37:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257766247.md)
  - [en](https://longbridge.com/en/news/257766247.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257766247.md)
generator: "portal-rs"
---

# U.S. stock market update: Sonnet BioTherapeutics up 17.80%

**U.S. Stock Market Midday Update**

**Stocks with High Trading Volume in the Industry**

AbbVie rose 2.38%, with increased trading volume. According to recent important news:

1.  On September 17, Berenberg raised AbbVie's target price from $170 to $270 and upgraded its rating from "Hold" to "Buy," directly driving the stock price up.

2.  On September 17, Morgan Stanley maintained its "Buy" rating on AbbVie and set a target price of $255, further boosting market confidence.

3.  On September 16, AbbVie announced it would continue to invest $10 billion in expansion plans in the U.S., demonstrating its confidence in future growth. The pharmaceutical industry faces policy risks, and investments should be cautious.

Roivant Sciences rose 10.83%, with a trading volume of $184 million. Based on recent key news:

1.  On September 17, Roivant Sciences and Priovant announced that their once-daily drug brepocitinib showed significant efficacy in a 52-week late-stage study for treating dermatomyositis, with patients showing improvement by week 4, and safety consistent with previous studies. This news drove the stock price up.

2.  On September 17, Roivant will hold an investor conference call to discuss these updates, further enhancing market confidence.

3.  On September 14, despite a quarterly net loss exceeding expectations, the stock price has risen 20% this year due to positive analyst ratings and investor optimism about Roivant's drug development approach. The biotechnology industry is performing strongly overall, with significant capital inflows.

Forte Biosciences rose 0.43%, with a trading volume of $171 million. According to recent key news:

1.  On September 17, Forte Biosciences announced significant progress in clinical trials for its new drug, driving the stock price up. The drug targets a rare disease, and market expectations for its potential sales are expected to increase significantly.

2.  On September 16, Forte Biosciences received an important patent grant, further solidifying its competitive position in the market. Investors are optimistic about the company's future profitability, leading to a rise in stock price.

3.  On September 15, Forte Biosciences released its latest quarterly financial report, showing that both its revenue and profit exceeded market expectations, boosting investor confidence and subsequently increasing the stock price. The pharmaceutical industry is performing strongly overall, supported by macroeconomic data.

**Stocks with High Market Capitalization in the Industry**

Amgen rose 1.13%. According to recent key news:

1.  On September 17, market analysis showed that although Amgen currently holds a rating among analysts, top analysts believe there are five stocks that are more worthy of purchase. This news may slightly shake investor confidence in Amgen, affecting its stock price volatility. Data source: MarketBeat

2.  On September 5th, Guggenheim maintained a hold rating on Amgen, indicating that the market is taking a wait-and-see approach towards Amgen's future performance, which may limit its stock price upside. Data source: Guggenheim.

3.  On September 3rd, Matt Phipps from William Blair gave Amgen a buy rating, and this positive assessment may have boosted market confidence in Amgen, driving the stock price up. Data source: William Blair. The healthcare sector has shown stable performance recently

### Related Stocks

- [SONN.US](https://longbridge.com/en/quote/SONN.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**